Skip to Content

Imprida

Active Substance: amlodipine (as besylate) / valsartan
Common Name: amlodipine / valsartan
ATC Code: C09DB01
Marketing Authorisation Holder: Novartis Europharm Ltd
Active Substance: amlodipine (as besylate) / valsartan
Status: Withdrawn
Authorisation Date: 2007-01-17
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Agents acting on the renin-angiotensin system

Therapeutic Indication

Treatment of essential hypertension.

Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

The marketing authorisation for Imprida has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide